Phibro Animal Health Q1 2027 Earnings Call Transcript

Phibro Animal Health (NASDAQ:PAHC) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.

Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more.

View the webcast at https://events.q4inc.com/attendee/646434646

Summary

Phibro Animal Health Corporation reported a 6% increase in net sales to $386.8 million and a 4% rise in adjusted EBITDA to $64.3 million for the fiscal first quarter ending September 30, 2026.

The company’s Performance Products and Mineral Nutrition segments showed strong growth, with increases of 16% and 17%, respectively, driven by higher commodity prices and strategic market positioning.

Animal Health segment sales grew 3%, with a notable decrease in virginiamycin sales in Brazil due to regulatory issues. The company remains hopeful for future approvals but has not included potential sales in guidance.

Phibro maintained its fiscal 2027 guidance, projecting net sales between $1.5 billion to $1.6 billion and adjusted EBITDA between $258 million to $262 million.

Operational highlights include the scheduled closure of the Chicago Heights plant in 2027 and efforts to reduce inventory levels to improve cash conversion.

Management expressed satisfaction with the quarter’s performance but emphasized the need for continued efforts, particularly in addressing inventory and cash flow.

Full Transcript

OPERATOR

We will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Glenn David, Chief Financial Officer. Glenn, please go ahead.

Glenn David (Chief Financial Officer)

Thank you, Kendra. Good day and welcome to the Phibro Animal Health Corporation earnings call for our fiscal first quarter ending September 30, 2026. My name is Glenn David and I am the Chief Financial Officer of Phibro Animal Health Corporation. I’m joined on today’s call by Donnie Bendheim, President and Chief Executive Officer, and Larry Miller, Chief Operating Officer. Also on today’s call is Patrick Rodriguez, our Treasurer and new Head of Investor Relations.

Welcome, Patrick, to the call and I’m going to turn things over to you.

Patrick Rodriguez (VP Finance and Treasurer)

Thank you, Glenn, and I look forward to interacting with all of you in the coming months. Today we will cover financial performance for our first quarter and provide financial guidance for our fiscal year ending June 30, 2027. At the conclusion of our remarks, we will open the lines for your questions. I would also like to remind you that we’re providing a simultaneous webcast of this call on our website, pahc.com. Also on the Investors section of our website you will find copies of the earnings press release and Quarterly Form 10-Q as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements section in our earnings press release.

Our remarks include references to certain financial measures which were not prepared in accordance with Generally Accepted Accounting Principles, or U.S. GAAP. I refer you to the Non-GAAP Financial Information section in our earnings press release for a discussion of these measures. Reconciliations of these Non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release.

We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items; unusual, non-operational or non-recurring items including stock-based compensation; other income/expenses as separately reported in the consolidated statements of operations including foreign currency losses/gains, net; income taxes related to pre-tax income adjustments; and unusual or non-recurring income tax items. Now let me introduce our President and Chief Executive Officer, Donnie Bendheim, to share his opening remarks.

Daniel Bendheim (President and Chief Executive Officer)

Thanks, Patrick, and good morning, everyone. Patrick, welcome to your first call. Fiscal 2027 is off to a good start. Sales grew 6% to $386.8 million and adjusted EBITDA grew 4% to $64.3 million. And we did that against a tough comparison coming off a very strong first quarter a year ago. Let me spend a few minutes on what drove the quarter and how we’re thinking about the rest of the year. Our two non-animal health segments did a lot of the heavy lifting this quarter. Performance Products grew 16% and Mineral Nutrition grew 17%. I want to spend a moment on Mineral Nutrition because I think it’s part of our business that tends to get overlooked. Part of this quarter’s growth reflects higher prices for zinc, copper and other underlying commodities.

And those prices obviously move up and down. But over time, we’ve also been moving this business toward the higher-margin, faster-growing parts of the market, including plant nutrition, dairy and pet food. Customers in these markets are asking for more on ingredient sourcing, quality, consistency and technical support. Those requirements play to our strengths because of the investments we’ve made in talent, facilities and processes. That’s a credit to the Mineral Nutrition management team who have been patient in building those relationships and capabilities.

We expect the business to continue growing in these higher-margin areas. In Animal Health, sales grew 3%, about right where we planned. MFAs were up 6% with good demand in North America and Asia and continued growth in ethanol processing aids. And that’s net of a $5.2 million decline in virginiamycin sales in Brazil. Nutritional Specialties and Vaccines were each down 2%, mostly on softer poultry purchases in North America and Brazil, plus some timing in Asia.

Now, people are still buying chicken. The pressure is on the producer side. Based on reports from several large protein companies over the last couple of weeks, U.S. chicken supply was up a little over 2%, which outpaced demand and pushed prices down. And producer margins have come off last year’s unusually strong levels. In Brazil, exports have been strong, but the domestic market was soft. The number of birds being raised is a healthy number and that’s ultimately what matters most for us.

When margins tighten, customers look harder at every input, cost and purchase. A producer accounts cost per pound can see what our products return. But some customers trim spending and cut inventory, and we saw a bit of that in our poultry sales this quarter, particularly in Nutritional Specialties and Vaccines. The underlying demand for chicken is there and we do well when it is. We see this pullback as temporary and we expect it to normalize over the course of this fiscal year.

Our forecast still has both of these product lines growing in the mid- to high-single digits for the year. Animal Health adjusted EBITDA in the quarter was down 1% from last year, though better than we had planned. Part of that reflects costs that move from the first quarter into the second. On virginiamycin in Brazil, the transition period ended in October. Our conversations with regulators about therapeutic claims are ongoing, and now that the Brazilian election has passed, we’re hopeful we’ll see some movements. We haven’t built any further virginiamycin sales in Brazil into this year’s numbers.

If an approval comes, it’s upside on the full year. We expect protein demand to continue growing, but producer profitability is likely to stay soft in the near term, and recent trade and disease disruptions in protein markets have added to the pressure. That’s reflected in our outlook. So we’re keeping our fiscal 2027 guidance where it was: net sales of $1.5 billion to $1.6 billion, adjusted EBITDA of $258 million to $262 million, and adjusted diluted EPS of $3.41 to $3.59.

Two other updates. First, the closure of our Chicago Heights plant remains on schedule. Production should wind down in the summer and early fall of 2027, with those products moving to our other Phibro plants and to contract manufacturers. Second, cash. We were cash positive in the quarter, but I am not satisfied. We’re carrying more inventory than we need and bringing it down this year is a priority for me and for our whole team. Better cash conversion gives us more flexibility on debt, on investment and on returns to shareholders.

So a good quarter with plenty of work still ahead. With that, let me turn the call over to Glenn.

Glenn David (Chief Financial Officer)

Thanks, Donnie. Starting with our Q1 performance on Slide 4, consolidated net sales for the quarter ended September 30, 2026 were $386.8 million, reflecting an increase of $22.9 million, or 6%, over the same quarter one year ago. The Animal Health segment grew 3% while Mineral Nutrition grew 17% and Performance Products grew 16%. Turning to the bottom line, net income for the first quarter was $29.5 million. That’s an increase of $3 million, or about 11%, compared to $26.5 million in the same quarter last year. Let me walk you through the key drivers. Operating income was down $1.6 million as higher SG&A more than offset the improvement we delivered in gross profit. Below the operating line, we saw several favorable items. First, net interest expense declined $0.8 million, reflecting lower interest rates and higher interest income, including interest received on our IEEPA tariff recoveries.

Second, foreign currency was a $0.4 million gain this quarter compared to a $2.0 million loss a year ago, a favorable swing of $2.4 million. And third, income tax expense was $0.5 million lower. Taken together, these items more than offset the lower operating income and drove the $3 million improvement in net income for the quarter. After making our standard adjustments to GAAP results, including acquisition-related items, foreign currency losses and certain one-off items, the first quarter adjusted EBITDA increased $2.4 million, or 4%, versus prior year. Adjusted net income of $32.4 million increased $2.5 million primarily due to higher gross profit, lower interest expense and a lower adjusted effective income tax rate, partially offset by higher adjusted SG&A due to higher employee-related costs.

Moving to segment level financial performance on Slide 5, the Animal Health segment posted $293 million net sales for the quarter, an increase of $9.6 million, or 3%, versus the same quarter prior year. Within the Animal Health segment, we reported MFAs and other net sales increase of $11.3 million, or 6%, due to increased demand for certain of our MFAs in North America and Asia and higher sales of ethanol processing aids, partially offset by a decrease of $5.2 million in virginiamycin sales in Brazil attributable to regulatory developments in the country.

Nutritional Specialties net sales decreased $1.1 million, or 2%, due to lower poultry demand in North America and decreased aquaculture demand in South America, partially offset by higher overall demand in China and higher companion animal sales. Vaccine net sales decreased by $0.6 million, or 2%, due to lower demand for poultry products in Brazil and lower sales in Asia, partly due to timing, offset by higher swine demand in North America and higher sales of adjuvant products.

Animal Health adjusted EBITDA decreased $1 million due to higher SG&A offsetting higher gross profit from increased sales. Moving on to first quarter financial performance for our other business segments on Slide 6, starting with Mineral Nutrition, net sales for the quarter were $73.6 million, an increase of $10.6 million, or 17%, due to an increase in demand and average selling prices for zinc oxide, copper and trace minerals. Looking at our Performance Products segment, net sales of $20.2 million reflects an increase of $2.7 million, or 16%, as a result of an increase in demand for copper-based and fluoride products.

Mineral Nutrition and Performance Products adjusted EBITDA increased $1.6 million and $1.2 million, respectively. Corporate expenses decreased $0.6 million driven by lower consulting and business development costs. Turning to key capitalization-related metrics on Slide 7, we generated $22 million of positive free cash flow for the 12 months ending September 30, 2026. We generated $86 million of operating cash flow and invested $64 million in capital expenditures. Cash and cash equivalents and short-term investments were $83 million at the end of the quarter. Our gross leverage ratio was 2.9 times at the end of the first quarter based on $740 million of total debt and $257 million of trailing twelve-month adjusted EBITDA.

Our net leverage ratio was 2.6 times at the end of the first quarter based on $656 million of net debt and $257 million of trailing 12-month adjusted EBITDA. On interest rates, there are no changes to our current swap arrangement. Turning to dividends, consistent with our history, we paid a quarterly dividend of $0.12 per share, or $4.9 million in aggregate. Now let’s turn to Slide 8, which lays out our guidance for fiscal year 2027. We are maintaining our previous guidance for fiscal year 2027 as follows: net sales of $1,550,000,000 to $1,600,000,000. This represents a growth range of 2% to 5% and a midpoint of approximately 4%. Total adjusted EBITDA of $258,000,000 to $268,000,000. This represents a growth range of 1% to 5% and a midpoint of approximately 3%. Our adjusted effective income tax rate for fiscal year 2027 is estimated at approximately 20% and includes the benefit of the resolution of a foreign tax audit expected in a future quarter.

We do expect our adjusted effective income tax rate to be higher in fiscal year 2028. Adjusted net income of $140 to $147 million. This represents growth of 6% to 11% with a midpoint of approximately 9%. GAAP net income assumes constant currency and no additional gains or losses from FX movements. As we look ahead to the second quarter, we want to highlight a comparability item. In the second quarter fiscal year 2026, net sales were reduced by approximately $13 million of product returns related to the transition of certain Tier 3 markets, including Canada and Europe, from Zoetis back to Phibro. Because this product was originally transferred at cost, the returns had no impact on gross profit. However, they lowered the prior-year net sales base.

As a result, reported second quarter net sales growth will benefit from an easier comparison. In addition, as Donnie mentioned, certain costs have shifted from Q1 to Q2. Based on these two dynamics, we expect revenue growth to be higher than EBITDA growth in Q2. In closing, we are pleased with the performance in our first quarter and the momentum we are carrying into the rest of fiscal year 2027. With that, Kendra, can you please open the lines for questions?

OPERATOR

We will now begin the question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question, from the line of Ekaterina at JPMorgan. Ekaterina, your line is open.

Please go ahead.

Ekaterina (Analyst)

Thank you so much. So first, just on virginiamycin in Brazil, you kind of mentioned this in the prepared remarks, but just maybe you can give a little bit more color on your thinking. You know, post elections, have there been any recent communications from regulators or just anything else that kind of gives you more or less confidence as you kind of think about, you know, the timing of that potential label? And then the next question I want to ask is just on your MFA portfolio. You know, can you just provide a little bit of, you know, some color in terms of, like, how much of the growth was coming from your legacy kind of portfolio versus the Zoetis portfolio? I know you’re no longer kind of breaking those out, but just the flavor of, you know, how much of the growth was coming kind of from both pieces.

And then last question is just on livestock trends kind of more broadly and how you’re thinking about the durability of growth for the industry and the trends that you’re kind of seeing, you know, both on the producer side and then also on the protein demand side of things. You’ve mentioned, you know, some of the stuff that’s happening on the poultry side, but maybe you can also talk about, you know, cattle and swine. Thanks.

Glenn David (Chief Financial Officer)

Thanks for the question, Ekaterina. I’ll start with the MFA portfolio and growth and then turn it to Larry and Donnie for virginiamycin and some of the livestock trends. In terms of the overall growth, as we mentioned, we’re not really breaking out between Zoetis and our legacy portfolio going forward. But just to give some context, obviously we said that we expected the Zoetis portfolio to be one of our higher growth contributors for the year, and we definitely saw that in the quarter.

Zoetis was a major contributor to the overall MFA growth in the quarter. On the legacy side, you know, we called out that our ethanol performance group had a very strong performance in the quarter as well. That helped offset the negative $5.2 million that we commented on for virginiamycin. So overall, you know, legacy, call it relatively flat because of the impact of virginiamycin offset by EPG, and then strong growth in our Zoetis portfolio. And then I’ll turn it to Donnie to talk about virginiamycin in Brazil.

Daniel Bendheim (President and Chief Executive Officer)

Yeah, so post-election we have not had any renewed contact yet with the regulators. We were not expecting to have, you know, in the week or two afterwards, any contact. We remain obviously overall bullish that, you know, eventually we will get the VM approval, as has happened basically in the rest of the world. But, you know, recognizing that things sometimes don’t move as quickly as we’d like it to move, we still, as we talked about, maintained our guidance that we have no VM sales in Brazil for the year.

And obviously if that changes, we will let you know.

Larry Miller (Chief Operating Officer)

Okay. I’ll talk a little bit about some of the protein profitability factors that we see—first, you know, what we’ve seen so far and then kind of what we expect to see and what some of the projections are going forward as we finish out the industry’s 2026 and into 2027. So, Donnie mentioned we do see squeezed producer margins in both our poultry segments as well as the swine industry. This is a factor of higher supply versus the demand, which has reduced wholesale prices for both chicken meat as well as pork prices.

Our customers have also experienced higher input costs, certainly with grain—primarily corn—but also in fuel and some of the other inflationary increases that they’ve seen. And this has caused the pricing pressure there. In the dairy segment, milk prices are hovering at farm gate around $20 per hundredweight. This is about a break-even for many dairy producers. One of the areas that producers have seen as far as profitability of their farm is the sale of day-old calves, which is still, you know, over $1,000 per calf—anywhere from $1,000, maybe up to $1,500 per calf. So that’s giving them some relief and some margin and profit opportunity.

In the beef sector, feedlot sector, we’ve—you know, the industry is seeing right now that some closeouts that happen between October and probably February will see negative margins on those, and that’s a factor that they had higher-priced feeder cattle coming in. The corn price was very high—and I’ll talk about that in a minute—and so that combination with the fat cattle price is going to have some negative closeouts for feedlots in the next few months.

We believe that that’s going to reverse as we get into 2027. One of the things that’s really changed—as you know, 75% of producers’ protein production cost is in feed, and corn is the main source of feed. If you look back over the last five weeks, cash corn was trading about $5.50 per bushel. That has now decreased to under four and a half. So we’ve taken a dollar a bushel out of feed cost. In USDA’s forecast in October, their corn report basically reported a little higher inventory—so pre-harvest inventory of corn stocks were a little bit higher—but also the yields, as we’re well into the harvest season now and will finish in the next few weeks, are higher than what they projected. So it looks like the pressure on profitability from corn, which is the main input cost, will be lower than what it has been and should be affordable for livestock production as we get into—finish 2026, but particularly as we get into 2027.

Ekaterina (Analyst)

Thanks. Appreciate all the color.

OPERATOR

Your next question, from the line of Curtis Moyles with BNP Paribas. Curtis, your line is open. Please go ahead.

Curtis Moyles (Analyst)

Hi, good morning. Thank you for taking my questions. I just have a couple here. So first I wanted to start on the adjusted EBITDA. It looks like that’s kind of progressed ahead of expectations in the first quarter. So I wanted to get a sense of why you decided not to raise guidance on that metric. Is it just because expenses were pushed a bit or are you also kind of baking in a little bit on that front? And then secondly, I wanted to see if you could share any color on the impact seen to date from the USDA’s phased reopening of the subm imports for livestock. Has that trended as expected, and maybe any color on what you’re thinking for 2027 on that. Thank you.

Glenn David (Chief Financial Officer)

Thanks, Curtis, for the question regarding EBITDA. We did perform a little better in the quarter than expected, having the EBITDA growth of 4%. As Donnie mentioned in his remarks, some of that was driven by Performance Products and Mineral Nutrition. But a good part was also driven by the fact that we did have some of the expenses shift from Q1 to future quarters. Also, we’re only one quarter into the year. You know, we just gave guidance about two months ago and the forecast still shows us within the guidance range.

So those factors are what’s contributing to us holding the EBITDA guidance at this point. Larry, you want to talk about the USDA?

Larry Miller (Chief Operating Officer)

Sure. So the border—the importation of live Mexican cattle coming across the border—there are currently three ports that are open now, three stations, two in New Mexico and one in Arizona. They are bringing across an average of about 700 animals per day. They’re projecting that in 2026 they will have imported 200,000 head of cattle, and the projection for 2027 is just over a million head of cattle that’ll be brought across the border for finishing in the United States.

So it is helping the supply into feedyards. Again, a million head, if that happens next year, over 27 million head that are fed for slaughter in feedlots, is a little under 4%. So it is making some impact. The other area that we’re seeing that is helping feedlot supply and beef supply is the amount of animals that are coming off the beef-on-dairy—coming off dairy. As I mentioned earlier, it is about five and a half million head that are being purpose-bred, if you will, and supplied into the beef chain. So that’s about 20% of, again, the 27 million head that we feed per year. So that’s a little bit of outlook—what we see currently and also into 2027 for incoming feeder cattle supply.

Curtis Moyles (Analyst)

Great. Thank you.

OPERATOR

There are no further questions at this time. I will now turn the call back to Glenn David for closing remarks.

Glenn David (Chief Financial Officer)

Thank you, Kendra. And thank you everyone for listening in on today’s call. We appreciate the time, attention, interest and support of Phibro Animal Health Corporation and hope you have a great day. Thank you.

OPERATOR

This concludes today’s call. Thank you for attending. You may now disconnect.

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company’s SEC filings and official press releases. Corporate participants’ and analysts’ statements reflect their views as of the date of this call and are subject to change without notice.